BOZEMAN, Mont., Dec. 14 /PRNewswire/ -- LigoCyte Pharmaceuticals Inc.
announces that Dr. J. Donald deBethizy has joined the company's Board of
Directors.
Dr. deBethizy has served as the president, CEO, and member of the board
of directors at Targacept (Nasdaq: TRGT) since August, 2000 and as
president and member of the board since March, 1997. He played a key role
in raising $138M in funding for the company's development programs,
including the successful completion of their IPO in April, 2006. Dr.
deBethizy has over 25 years of experience in research and development,
including over 10 years in executive positions in the biopharmaceutical
field. He has been certified as a Diplomate of the American Board of
Toxicology since 1985 and received his M.S. and Ph.D. degrees from Utah
State University in Logan, Utah. He currently has adjunct professor
appointments at Wake Forest University and Duke University, both in North
Carolina. Dr. deBethizy received the Entrepreneur of the Year, Emerging
Companies from Carolinas Ernst & Young in 2002. He also serves as a member
of the governing body committee for emerging companies in the international
BIO trade organization.
"We are pleased to welcome Don deBethizy to our board," said Donald P.
Beeman, LigoCyte's CEO. "His international & biopharmaceutical experience,
business leadership and venture capital knowledge will be of particular
benefit to LigoCyte as we raise our third round of investment financing and
move our Norovirus vaccine into the clinic early next year."
About LigoCyte:
LigoCyte, established in 1998, is breaking new ground in the prevention
and treatment of infectious diseases and inflammation. The company has
produced a number of novel drug compounds that stimulate or suppress immune
responses. LigoCyte is advancing its proprietary products into human
clinical testing, positioning the company for continued growth and success
in the biotechnology industry. For additional information on LigoCyte,
please visit http://www.ligocyte.com.
Binding Science. Better Medicine.
SOURCE LigoCyte Pharmaceuticals Inc.
 back to top
Related links:
http://www.ligocyte.com
CONTACT:
Karen Sipes, Ph.D., Director, Marketing &
Communications of LigoCyte Pharmaceuticals, Inc.,
+1-406-556-9228, karen.sipes@ligocyte.com
|
